Precision Biosciences Inc (DTIL) concluded trading on Wednesday at a closing price of $4.24, with 8.2 million shares of worth about $34.79 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -7.83% during that period and on June 25, 2025 the price saw a loss of about -7.22%. Currently the company’s common shares owned by public are about 10.55M shares, out of which, 8.11M shares are available for trading.
Stock saw a price change of -13.47% in past 5 days and over the past one month there was a price change of -7.42%. Year-to-date (YTD), DTIL shares are showing a performance of -54.89% which increased to 11.29% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.61 but also hit the highest price of $11.09 during that period. The average intraday trading volume for Precision Biosciences Inc shares is 129.60K. The stock is currently trading -14.39% below its 20-day simple moving average (SMA20), while that difference is down -16.05% for SMA50 and it goes to -31.16% lower than SMA200.
Precision Biosciences Inc (NASDAQ: DTIL) currently have 10.55M outstanding shares and institutions hold larger chunk of about 34.11% of that.
The stock has a current market capitalization of $47.01M and its 3Y-monthly beta is at 1.46. It has posted earnings per share of -$2.01 in the same period. It has Quick Ratio of 6.62 while making debt-to-equity ratio of 0.60. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for DTIL, volatility over the week remained 4.66% while standing at 3.78% over the month.
Stock’s fiscal year EPS is expected to drop by -781.73% while it is estimated to increase by 33.25% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BMO Capital Markets on January 10, 2025 offering an Outperform rating for the stock and assigned a target price of $34 to it. Coverage by Guggenheim stated Precision Biosciences Inc (DTIL) stock as a Buy in their note to investors on April 30, 2024, suggesting a price target of $19 for the stock. Stock get a Buy rating from BTIG Research on July 27, 2020.
